CDKN2A and neoplasm: Assessing pre-treatment tumor samples, 54 patients (73%) presented with increased PLK3 expression, 33 (44.6%) with increased pT273 Caspase 8 levels, and 47 (63.5%) with high p16INK4a detection (Table 1).